Skip to main content
. 2014 Jan 3;9(1):e84513. doi: 10.1371/journal.pone.0084513

Figure 7. Type I IFN induces ISGs and inhibits HIV-1 BaL replication in IL2/PHA PBMCs.

Figure 7

(A) IL2/PHA PBMCs were infected with SeV (MOI 0.5) or treated with IFNα (20 ng/mL). Total RNA was harvested after 6 hours for RT-qPCR measurements of ISG56 mRNA. (B) IL2/PHA PBMCs were pre-treated with IFNβ in increasing doses 16 hours prior to infection with HIV-1 Bal (MOI 0.002). Levels of p24 were measured in the supernatants 72 hours post infection. (C–E) IL2/PHA PBMCs were infected with HIV-1 BaL (MOI 0.002) or SeV (MOI 0.5) or mock infected. Total RNA was harvested after 12, 24, and 36 hours for RT-qPCR measurements of (C) ISG56, (D) CXCL10, and (E) viperin mRNAs.